774230-98-7

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(5-bromo-1,3-thiazol-2-yl)ethan-1-one is utilized as an intermediate in the synthesis of pharmaceuticals for its ability to facilitate the creation of a variety of drug molecules. The presence of the thiazole ring and the ketone group allows for the compound to be a part of diverse chemical reactions, contributing to the development of new medications.
Used in Agrochemical Production:
In the agrochemical industry, 1-(5-bromo-1,3-thiazol-2-yl)ethan-1-one is employed as an intermediate in the synthesis of various agrochemicals. Its chemical properties make it suitable for the development of compounds used in crop protection and other agricultural applications.
Used in Organic Chemistry Research:
1-(5-bromo-1,3-thiazol-2-yl)ethan-1-one is used as a research tool in organic chemistry due to its unique structure and properties. It aids in the exploration of new chemical reactions and the synthesis of novel organic compounds, advancing the field of organic chemistry.
Used in Materials Research:
1-(5-bromo-1,3-thiazol-2-yl)ethan-1-one is also valuable in materials research, where its structural attributes can be leveraged to develop new materials with specific properties for various applications, such as in electronics, coatings, or other industrial materials.

Upstream product

• 3034-55-7 5-bromo-1,3-thiazole 
• 110-05-4 di-tert-butyl peroxide 
• 201230-82-2 carbon monoxide 
• 24295-03-2 2-Acetylthiazole 
• 200440-13-7 2-(1,1-Dimethoxyethyl)thiazole 
• 774230-97-6 5-bromo-2-( 1,1-dimethoxyethyl)thiazole 
• 24295-06-5 2-(2-methyl-1,3-dioxolan-2-yl)-1,3-thiazole 

Relevant academic research and scientific papers

USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VIII

The present invention relates to the use of strobilurin type compounds of formula I and the N-oxides and the salts thereof for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein (also referred to as F129L mutation in the mitochondrial cytochrome b gene) conferring resistance to Qo inhibitors, and to methods for combating such fungi. The invention also relates to novel compounds, processes for preparing these compounds, to compositions comprising at least one such compound, and to seeds coated with at least one such compound.

NLRP3 INHIBITORS

The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3inhibition.

Carbonylative Acetylation of Heterocycles

Herein, a new procedure for the carbonylative acetylation of heterocycles has been developed. In this process, organic peroxide acts as the methyl source. Various heterocycles were transformed into the corresponding methyl heterocyclic ketones in moderate to good yields.

CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME

The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.

FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

no abstract published

DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

ANTIVIRAL COMPOUNDS COMPOSED OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C

The present invention relates to novel Linked Tricyclic Aryl Compounds, compositions comprising at least one Linked Tricyclic Compound, and methods of using Linked Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient. in one aspect, the present invention provides Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein: Non-limiting examples of the Compounds of Formula (II) include compound 56

THIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES

The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.